Abstracts

PHARMACOGENETICS OF DOLUTEGRAVIR PLASMA EXPOSURE AMONG SOUTH AFRICANS LIVING WITH HIV

Dolutegravir (DTG) is a component of preferred first-line antiretroviral therapy (ART) regimens. DTG is metabolized primarily by UGT1A1, and UGT1A1 variants affect DTG plasma exposure. There are limited data on DTG pharmacogenetics in Africa. We characterized genetic associations with estimated plasma DTG area under the concentration-time curve (AUC) among African participants who initiated DTG-containing ART…

PHARMACOKINETIC STUDY OF ISLATRAVIR & ETONOGESTREL IMPLANTS IN MACAQUES

Prevention of HIV and unintended pregnancies are public health priorities. We assessed the pharmacokinetics of ?-polycaprolactone implants containing the antiretroviral islatravir (ISL) and the contraceptive etonogestrel (ENG) in macaques. ISL implants (100µm wall thickness) were administered subcutaneously in the right arm with a trocar. Group-1 (n=3) received a low-dose (LD) and group-2 (n=3) received a…

NEXT-GENERATION ISLATRAVIR/ETONOGESTREL/ETHINYL ESTRADIOL MPT INTRAVAGINAL RING

Multipurpose prevention technologies (MPTs) are of interest to prevent unintended pregnancy and HIV. Uniquely designed, geometrically complex 3D printed intravaginal rings (IVRs) are an attractive delivery platform that can provide controlled drug release and tunable product user characteristics. We evaluated drug release, elimination, and safety of an MPT IVR in sheep and an Islatravir (EFdA)-eluting,…